Autolus Therapeutics (AUTL) Accounts Payables (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Accounts Payables data on file, last reported at $3.1 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 56.58% year-over-year to $3.1 million; the trailing twelve-month figure through Dec 2025 stood at $3.1 million (up 56.58% YoY), and the FY2025 full-year result was $3.1 million, up 56.58% from the prior year.
• Accounts Payables for Q4 2025 stood at $3.1 million, down from $11.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.0 million in Q3 2025 and bottomed at -$1.3 million in Q2 2021.
• The 5-year median for Accounts Payables is $808000.0 (2021), against an average of $1.7 million.
• The widest annual swing landed in 2021, when Accounts Payables plunged 139.21%; it then jumped 1955.07% in 2024.
• A 5-year view of Accounts Payables shows it stood at $431000.0 in 2021, then gained by 23.2% to $531000.0 in 2022, then plunged by 80.6% to $103000.0 in 2023, then jumped by 1811.65% to $2.0 million in 2024, then jumped by 56.58% to $3.1 million in 2025.
• The last three Accounts Payables figures came in at $3.1 million (Q4 2025), $11.0 million (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.

Peer Comparison